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We report the case of a 71-year-old woman with nivolumab-induced colitis, which was successfully treated
with corticosteroid treatment. She underwent left-sided nephrectomy for renal cell carcinoma in 1989 at 43 years
of age. Sorafenib was initiated in 2015 owing to progression of lung and adrenal metastasis; however, it was dis-
continued in 2016 secondary to nausea. In March 2017, she was switched to nivolumab administered as a bi-
weekly dose of 3.0 mg/kg/day to treat worsening lung and adrenal metastasis. A partial response was observed
after the administration of 7 cycles of nivolumab. In August 2017, she developed vomiting, severe diarrhea, and
high fever after the administration of 10 cycles of nivolumab, necessitating admission to our hospital on an emer-
gency basis. Initially, we suspected both, infectious enteritis and nivolumab-induced colitis, and she received
meropenem; however, her symptoms persisted. Computed tomography showed intestinal wall thickening com-
patible with nivolumab-induced colitis. Thus, we initiated intravenous methylprednisolone therapy at a dose of 2.5
mg/kg/day. Her symptoms improved soon after the initiation of steroid, without any relapse. Nivolumab was dis-
continued based on the Immune-mediated Adverse Reactions Management Guide. Nivolumab-induced colitis
may precipitate medical emergencies. Therefore, clinicians should be familiar with this condition and its appropri-
ate management.
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Figure　1　Abdominal CT. 


















与 7コース終了後の CT（computed tomography）所
見では標的病変が右副腎で 46％減少，右肺下葉で
33％縮小と部分奏功であった．10コース投与後 7
日目の 2017年 8月 7日より発熱と 6回/日程度の下
痢がみられ入院となったが，絶食および補液により
症状軽快し入院後 7日目に退院となった．しかし退











た．生化学所見は Alb 2.5 g/dl，CRP 10.55 mg/dl，LD
205 IU/L，ALP 136 IU/L，γ-GTP 19 IU/L，BUN 12.4
mg/dl，Cr 1.51 mg/dl，UA 6.8 mg/dl，Na 136 mEq/



















minology criteria for adverse events：CTCAE）










Figure　2　Clinical course during admission.
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